Notably, the significant longitudinal NfL decrease observed in patients treated with tofersen, an antisense oligonucleotide targeting SOD protein in SOD1‐associated ALS, preceded the clinical outcome and played a decisive role in its Food and Drug Administration approval [30]. Here, SOD1 is linked to amyotrophic lateral sclerosis.